000658

18. 12‑month effects of incretins versus SGLT2‑Inhibitors on cognitive performance and metabolic profile / S. Perna, M. Mainardi, P. Astrone [et al.] // A randomized clinical trial in the elderly with Type‑2 diabetes mellitus. Clin Pharmacol. 2018;10:141–151. https://doi.org/10.2147/CPAA.S164785 19. Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis / R. Peters, S. Yasar, C.S. Anderson [et al.] // Neurology. 2020 Jan 21;94 (3): e267‑e281. doi: 10.1212/WNL.000000 0000008732. Epub 2019Dec 11. PMID: 31827004; PMCID: PMC7108807.]. 20. J: Evaluation of High Cholesterol and Risk of Dementia and Cognitive Decline in Older Adults Using Individual Patient Meta-Analysis / R. Peters, Y. Xu, R. Antikainen [et al.] // Dement Geriatr Cogn Disord 2021;50:318–325. doi: 10.1159/000519452. 21. (2014) Examination of the FDA Warning for Statins and Cognitive Dysfunction / F.M. Sahebzamani, C.L. Munro, O.C. Marroquin [et al.] // J Pharmacovigilance 2: 141. doi:10.4172/2329–6887.100014. 22. 2020 International Society of Hypertension global hypertension practice guidelines / T. Unger, C. Borghi, Charchar F. [et al.] // J Hypertens. – 2020 Jun;38 (6):982–1004. doi: 10.1097/HJH.0000000000002453. PMID: 32371787. 23. World Alzheimer Report 2015 – The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends / M. J. Prince, A. Wimo, M.M. Guerchet [et al.]. – London: Alzheimer's Disease International. – 2015. – 84 p. 24. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial / J.D. Williamson, N.M. Pajewski, A.P. Auchus [et al.] // JAMA 2019; 321 (6): 553–661. DOI: 10.1001/ jama.2018.2144.